Skip to main content
SpringerLink
Log in

Long-term ibrutinib: hypertension common but manageable

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity Cancer : 5 Apr 2023. Available from: URL: https://doi.org/10.1002/cncr.34787

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Long-term ibrutinib: hypertension common but manageable. Reactions Weekly 1952, 11 (2023). https://doi.org/10.1007/s40278-023-37104-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-37104-3

Search

Navigation